NEFL and myeloid sarcoma: The most extensively investigated marker for axonal damage is neurofilament light chain (NfL), which was shown to be elevated in the cerebrospinal fluid (CSF) of MS patients, correlating with MRI parameters of patients and being a potential prognostic biomarker (8–11).